Health & Fitness
Wed, February 22, 2012
PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that Edward J. Quilty, president and chief executive officer, will present to investors as part of the LHA Life Sciences & Medical Technologies Virtual Conference on Thursday, February 16, 2012 at 9:30 a.m. Eastern. The presentation will provide a corporate overview and a discussion of the Companyas growth strategy.
Interested parties can access the audio webcast with slide presentation at [ www.dermasciences.com ], or from the PrecisionIR event site: [ http://www.investorcalendar.com/IC/CEPage.asp?ID=167329 ].
An archived presentation will be available for 30 days.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products, advanced wound care dressings and traditional dressings. Derma Sciences has successfully completed the treatment phase of a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, and BIOGUARD for infection prevention.
For more information please visit [ www.dermasciences.com ].
